Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long duration mild temperature hyperthermia and brachytherapy.

E P Armour1, G P Raaphorst

  • 1Department of Radiation Oncology, William Beaumont Hospital, 3811 West Thirteen Mile Road, Royal Oak, MI 48073, USA. warmour@beaumont.edu

International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
|June 16, 2004
PubMed
Summary

Combining long duration mild temperature hyperthermia (LDMH) with low dose-rate (LDR) brachytherapy enhances cancer cell killing by inhibiting sublethal damage repair. This combined therapy shows significant potential for clinical application due to its biological rationale and technical feasibility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear magnetic resonance study of mammalian cell water influence of water content and ionic environment.

Biophysical journal·2009
Same author

Fitting the linear-quadratic model to detailed data sets for different dose ranges.

Physics in medicine and biology·2006
Same author

Evaluation of adaptive responses to cisplatin in normal and mutant cell lines with mutations in recombination repair pathways.

Anticancer research·2006
Same author

Response to pulsed dose rate and low dose rate irradiation with and without mild hyperthermia using human breast carcinoma cell lines.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2006
Same author

The evaluation of thermal cisplatin sensitization in normal and XP human cells using mild hyperthermia at 40 and 41 degrees C.

Anticancer research·2005
Same author

Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair.

Oncology reports·2005

Area of Science:

  • Oncology
  • Radiation Oncology
  • Biophysics

Background:

  • Long duration mild temperature hyperthermia (LDMH) combined with low dose-rate (LDR) brachytherapy has been proposed to improve cancer treatment efficacy.
  • Research exploring LDMH interactions with various brachytherapy types, including pulsed and high dose-rate, provides context for LDMH/LDR brachytherapy.

Purpose of the Study:

  • To review cellular and tumor research supporting the hypothesis of enhanced cancer cell killing through LDMH and LDR brachytherapy.
  • To compare LDMH interactions with different brachytherapy modalities and elucidate the mechanisms of LDR sensitization.

Main Methods:

  • Review of existing cellular and tumor research on LDMH and brachytherapy.
  • Comparison of LDMH interactions with pulsed, high dose-rate, and LDR brachytherapy using clinically relevant parameters.

Related Experiment Videos

  • Analysis of molecular mechanisms, including DNA repair inhibition and tumor blood flow modification.

    • Main Results:

    • LDMH sensitizes LDR brachytherapy primarily by inhibiting sublethal damage repair, involving DNA repair enzymes.
    • LDMH can decrease the hypoxic fraction in tumors by modifying tumor blood flow.
    • Potential therapeutic ratio enhancement (TER) of approximately 2 is expected, with minimal toxicity and thermotolerance effects.

    Conclusions:

    • Combined LDMH and LDR brachytherapy possesses a strong biological rationale and sufficient technical advancements for clinical application.
    • This combined modality is ready for clinical testing due to its achievable thermal goals, lack of toxicity, and potential to enhance radiation and chemotherapy efficacy.